Ricevi le ultime notizie sulle azioni Adicet Bio con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ACET

Ultime notizie per

Adicet Bio

Adicet Bio Inc

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Atossa Therapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Biomea Fusion

Citius Oncology

Fate Therapeutics

Gain Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

InflaRx

Immunic

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

MDxHealth

Macrogenics

Oncolytics Biotech

Ovid Therapeutics

Pelthos Therapeutics

Quince Therapeutics

Surrozen

Tharimmune

Instil Bio

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Adicet Bio (ACET) Previsione

Notizie

Utili

Quote.Nav.option-chain

Dividendi

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Comments

Adicet Bio Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO